A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer

Jessica R. Walter, Mary E. Lohman, Shilajit D. Kundu, Shuai Xu*

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The vast majority of patients diagnosed with testicular germ cell tumors will survive their disease. This raises the importance of survivorship issues, particularly fertility preservation given that half of patients diagnosed with testicular cancer are under the age of 34. In this perspective, we offer a novel fertility rating system based on the FDA's A/B/C/D/X/N pregnancy risk category system for first line therapies (surgical, chemotherapeutic, and radiation therapies) listed by the National Comprehensive Cancer Network (NCCN). All chemotherapies (bleomycin, carboplatin, cisplatin, etoposide and ifosfamide) have available human data demonstrating a negative impact on fertility yielding category D ratings. Radiation therapy and surgical interventions such as unilateral orchiectomy and retroperitoneal lymph node dissections (RLND) were also designated category D. Despite the clear risk to fertility, the majority of men do not undergo semen cryopreservation (SCP). Future efforts should be made to reduce the barriers to reproductive counseling and fertility preservation for testicular cancer survivors.

Original languageEnglish (US)
Pages (from-to)S778-S781
JournalTranslational Cancer Research
Volume5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Testicular Neoplasms
Fertility Preservation
Fertility
Radiotherapy
Drug Therapy
Ifosfamide
Orchiectomy
Carboplatin
Cryopreservation
Bleomycin
Etoposide
Semen
Lymph Node Excision
Cisplatin
Survivors
Counseling
Survival Rate
Pregnancy
Neoplasms
Therapeutics

Keywords

  • Fertility preservation
  • Fertility risk
  • Germ cell tumors
  • Semen cryopreservation (SCP)
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{7e5deabdfc974d21badd36525ba8fdeb,
title = "A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer",
abstract = "The vast majority of patients diagnosed with testicular germ cell tumors will survive their disease. This raises the importance of survivorship issues, particularly fertility preservation given that half of patients diagnosed with testicular cancer are under the age of 34. In this perspective, we offer a novel fertility rating system based on the FDA's A/B/C/D/X/N pregnancy risk category system for first line therapies (surgical, chemotherapeutic, and radiation therapies) listed by the National Comprehensive Cancer Network (NCCN). All chemotherapies (bleomycin, carboplatin, cisplatin, etoposide and ifosfamide) have available human data demonstrating a negative impact on fertility yielding category D ratings. Radiation therapy and surgical interventions such as unilateral orchiectomy and retroperitoneal lymph node dissections (RLND) were also designated category D. Despite the clear risk to fertility, the majority of men do not undergo semen cryopreservation (SCP). Future efforts should be made to reduce the barriers to reproductive counseling and fertility preservation for testicular cancer survivors.",
keywords = "Fertility preservation, Fertility risk, Germ cell tumors, Semen cryopreservation (SCP), Testicular cancer",
author = "Walter, {Jessica R.} and Lohman, {Mary E.} and Kundu, {Shilajit D.} and Shuai Xu",
year = "2016",
month = "1",
day = "1",
doi = "10.21037/tcr.2016.10.90",
language = "English (US)",
volume = "5",
pages = "S778--S781",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer. / Walter, Jessica R.; Lohman, Mary E.; Kundu, Shilajit D.; Xu, Shuai.

In: Translational Cancer Research, Vol. 5, 01.01.2016, p. S778-S781.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer

AU - Walter, Jessica R.

AU - Lohman, Mary E.

AU - Kundu, Shilajit D.

AU - Xu, Shuai

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The vast majority of patients diagnosed with testicular germ cell tumors will survive their disease. This raises the importance of survivorship issues, particularly fertility preservation given that half of patients diagnosed with testicular cancer are under the age of 34. In this perspective, we offer a novel fertility rating system based on the FDA's A/B/C/D/X/N pregnancy risk category system for first line therapies (surgical, chemotherapeutic, and radiation therapies) listed by the National Comprehensive Cancer Network (NCCN). All chemotherapies (bleomycin, carboplatin, cisplatin, etoposide and ifosfamide) have available human data demonstrating a negative impact on fertility yielding category D ratings. Radiation therapy and surgical interventions such as unilateral orchiectomy and retroperitoneal lymph node dissections (RLND) were also designated category D. Despite the clear risk to fertility, the majority of men do not undergo semen cryopreservation (SCP). Future efforts should be made to reduce the barriers to reproductive counseling and fertility preservation for testicular cancer survivors.

AB - The vast majority of patients diagnosed with testicular germ cell tumors will survive their disease. This raises the importance of survivorship issues, particularly fertility preservation given that half of patients diagnosed with testicular cancer are under the age of 34. In this perspective, we offer a novel fertility rating system based on the FDA's A/B/C/D/X/N pregnancy risk category system for first line therapies (surgical, chemotherapeutic, and radiation therapies) listed by the National Comprehensive Cancer Network (NCCN). All chemotherapies (bleomycin, carboplatin, cisplatin, etoposide and ifosfamide) have available human data demonstrating a negative impact on fertility yielding category D ratings. Radiation therapy and surgical interventions such as unilateral orchiectomy and retroperitoneal lymph node dissections (RLND) were also designated category D. Despite the clear risk to fertility, the majority of men do not undergo semen cryopreservation (SCP). Future efforts should be made to reduce the barriers to reproductive counseling and fertility preservation for testicular cancer survivors.

KW - Fertility preservation

KW - Fertility risk

KW - Germ cell tumors

KW - Semen cryopreservation (SCP)

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84996773839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996773839&partnerID=8YFLogxK

U2 - 10.21037/tcr.2016.10.90

DO - 10.21037/tcr.2016.10.90

M3 - Article

VL - 5

SP - S778-S781

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -